dc.contributor.author
Trippel, Tobias Daniel
dc.contributor.author
Mende, Meinhard
dc.contributor.author
Düngen, Hans‐Dirk
dc.contributor.author
Hashemi, Djawid
dc.contributor.author
Petutschnigg, Johannes
dc.contributor.author
Nolte, Kathleen
dc.contributor.author
Herrmann‐Lingen, Christoph
dc.contributor.author
Binder, Lutz
dc.contributor.author
Hasenfuss, Gerd
dc.contributor.author
Pieske, Burkert
dc.contributor.author
Wachter, Rolf
dc.contributor.author
Edelmann, Frank
dc.date.accessioned
2021-11-18T13:18:08Z
dc.date.available
2021-11-18T13:18:08Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/32767
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-32493
dc.description.abstract
Aims: Galectin-3 (Gal-3) predicts long-term outcome among patients with heart failure (HF) with preserved ejection fraction (HFpEF). The ability of Gal-3 to diagnose and predict incident HFpEF in a cohort at risk for HFpEF is of particular interest. We aimed to determine the association between Gal-3 and clinical manifestations of HFpEF, the relationship between Gal-3 and all-cause mortality, or the composite of cardiovascular hospitalization and death.
Methods and results: The observational Diast-CHF study included patients aged 50 to 85 years with ≥1 risk factor for HF (e.g. hypertension, diabetes mellitus, and atherosclerotic disease) or previously suspected HF. Patients were followed for 10 years. The association between Gal-3, evidence of diastolic dysfunction, and Framingham criteria for HF was examined. All deaths and hospitalizations were adjudicated as cardiovascular or non-cardiovascular. The analysis population was composed of 1386 subjects (67 years old, 50.9% female). The area under the receiver operating characteristic curve to diagnose HFpEF was 0.71. At a cut-off value of 13.57 ng/mL, sensitivity was 0.61 and specificity was 0.73 for Gal-3, and the diagnostic power to detect HFpEF was superior to N-terminal pro-brain natriuretic peptide (area under the receiver operating characteristic curve 0.59, P > 0.001). Baseline Gal-3 was associated with risk factors for HF (P < 0.001). Higher levels of Gal-3 predicted incident HFpEF (P < 0.05), adjusted all-cause mortality (P < 0.001), and the adjusted composite of cardiovascular hospitalization and death (P < 0.001), both independent from N-terminal pro-brain natriuretic peptide.
Conclusions: Gal-3 differentiated patients with HFpEF from an overall cohort of well-characterized patients with risk factors for HFpEF. Independent of other factors, baseline Gal-3 levels were associated with a higher risk for incident HFpEF, mortality, or the composite of cardiovascular hospitalization and death over 10 year follow-up. In conjunction with clinical parameters, Gal-3 adds a statistically significant value for the diagnosis of HFpEF within this study, yet the clinical relevance remains debatable.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
Heart failure
en
dc.subject
Risk prediction
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1002/ehf2.13174
dcterms.bibliographicCitation.journaltitle
ESC Heart Failure
dcterms.bibliographicCitation.number
2
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
829
dcterms.bibliographicCitation.pageend
841
dcterms.bibliographicCitation.volume
8
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33566456
dcterms.isPartOf.eissn
2055-5822